Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.